

Correction: Cochlear implantation for tinnitus in adults with bilateral hearing loss: protocol of a randomised controlled trial

Assouly K, Smit AL, Stegeman I, *et al.* Cochlear implantation for tinnitus in adults with bilateral hearing loss: protocol of a randomised controlled trial. *BMJ Open* 2021;11:e043288. doi: 10.1136/bmjopen-2020-043288

An amendment to the protocol resulted in the change of one inclusion criteria of the study. The inclusion criteria ‘pure tone average at 0.5, 1, 2 and 4 kHz: bilateral threshold between 50 and ≤ 75 dB’ has been changed to ‘pure tone average at 0.5,1,2 kHz: bilateral threshold between ≥ 40 and ≤ 80 dB and hearing thresholds in the ear to be implanted (≥ 4 kHz) ≥ 50 dB’. The correction of the inclusion criteria does not change the aim and the design of the study, but for clarification, the following correction are noted:

1. The inclusion criteria in the ‘Methods and analysis’ section of the Abstract should be: (Tinnitus Functional Index (TFI) > 32 , Beck’s Depression Index < 19 , pure tone average at **0.5,1,2 kHz** bilateral threshold **between ≥ 40 and ≤ 80 dB and hearing thresholds in the ear to be implanted (≥ 4 kHz) ≥ 50 dB**).
2. In the Method and analysis section, in the Inclusion criteria paragraph, the hearing level criteria should be:
 - Audiometry (Pure Tone Average (PTA) at **0.5,1,2 kHz**: bilateral threshold **between ≥ 40 and ≤ 80 dB**.
 - **Hearing thresholds in the ear to be implanted (≥ 4 kHz) ≥ 50 dB**
 - Hearing threshold stability (PTA < 5 dB change for 1 year in each ear).’
3. Figure 1 has been updated with the correction of the inclusion criteria.





Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

BMJ Open 2022;**12**:e043288corr1. doi:10.1136/bmjopen-2020-043288corr1

